Silvia Noiman

Silvia Noiman is a life sciences entrepreneur and former Venture Partner at Pontifax Venture Capital, where she specialized in scaling early-stage healthcare and biotechnology innovations. She holds a doctorate from Tel-Aviv University and has built an extensive career translating complex scientific discoveries into commercially viable medical technologies. During her executive tenure at Pontifax, a prominent investment firm originally co-founded by former Teva Pharmaceuticals chief executive Eli Hurvitz, she evaluated and guided investments across a $1.2 billion life sciences portfolio comprising approximately 100 distinct companies. Operating as both an investor and a founder, Noiman recently co-founded IMEL, an emerging biotechnology startup dedicated to developing novel cell-based therapies specifically targeting mitochondrial biology and dysfunction. Her professional background centers on bridging the critical gap between academic research and commercial biotechnology development to successfully advance transformative medical treatments globally.